The 11th International Forum on Rheumatoid Arthritis: Pathogenesis and Emerging Therapeutic Strategies (IFRA 2019) was designed to bring together leading rheumatologists from Europe, the United States and Asian countries working to better understand the pathogenesis and emerging therapeutic strategies in rheumatoid arthritis (RA). The field of rheumatology has made great advances in recent years through consortia-based efforts, including the Accelerating Medicines Partnership® Program (AMP® RA/SLE) and the Rheuma Tolerance for Cure (RTCure), as well as disease-focused groups such as the International Forum on Rheumatoid Arthritis (IFRA). Providing a joint congress for international leaders from each of these impactful partnerships to interact and collaborate is essential to harmonize strategic priorities, discuss prominent Research datasets, and advance novel technologies at the RA frontier to move the field forward. Challenges in RA that remain unsolved include disease heterogeneity as well as uneven responsiveness to existing and novel treatment regimens. For promoting next-generation rheumatology, we must convene and construct global networks to best treat and serve our patients worldwide.
The Forum was held on September 25th – 27th, 2019 in Washington, D.C. at the Washington Marriott at Metro Center.
Results & Accomplishments
BMJ Journals. Annals of the Rheumatic Diseases (March 2020): Disruptive innovation in rheumatology: new networks of global public–private partnerships are needed to take advantage of scientific progress
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)*
Sponsoring Consortia Partners:
- Accelerating Medicines Partnership RA/SLE*
- Innovative Medicines Initiative*
- International Forum for Rheumatoid Arthritis*
- Rheuma Tolerance for Cure (RTCure)*
*provides financial or in-kind support for this program.
Accelerating Medicines Partnership (AMP)
Innovative Medicines Initiative (IMI) and Rheuma Tolerance for Cure (RTCure)
International Forum for Rheumatoid Arthritis (IFRA)
National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Steve Hoffmann, Associate Vice President, Research Partnerships, [email protected]
ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.